Bitartrate

Zanoprima Launches Commercial Production of Its High Purity Tobacco-Free Synthetic (S) Nicotine Using Revolutionary Patented New Process

Retrieved on: 
Monday, October 11, 2021
Retail, Health, Tobacco, Other Health, Specialty, General Health, TSNA, Dementia, Nicotine, Multimedia, USP, Carcinogen, IBA Lifesciences, Propylene glycol, Bitartrate, Death, Compliance, Tobacco, Sodium, Taste, Retail, Health, Tobacco, Other Health, Specialty, General Health

Zanoprima Lifesciences ( www.zanoprima.com ) ( https://www.linkedin.com/company/zanoprima/ ) a UK based company, announced commercial production of its high purity synthetic (S)-Nicotine (SyNic) using a revolutionary patented process that does not involve the use of tobacco or any synthetic racemic mixture.

Key Points: 
  • Zanoprima Lifesciences ( www.zanoprima.com ) ( https://www.linkedin.com/company/zanoprima/ ) a UK based company, announced commercial production of its high purity synthetic (S)-Nicotine (SyNic) using a revolutionary patented process that does not involve the use of tobacco or any synthetic racemic mixture.
  • Zanoprima has developed and patented the process to manufacture high purity (typically 99.9%), synthetic (S)-Nicotine (SyNic) for commercial use that is free of TSNA (tobacco-specific Nitrosamines), toxins, carcinogens, odour, and harsh taste.
  • Green Chemistry principles compliant production process minimizes the environmental impacts of nicotine production.
  • As a responsible synthetic nicotine (SyNic) manufacturer Zanoprima will distribute SyNic in strict compliance with regulations in each of its markets, globally.

Evofem Biosciences to Report Second Quarter 2021 Results and Provide Corporate Update on Wednesday, August 11, 2021

Retrieved on: 
Wednesday, July 28, 2021
Chemical substances, Chemistry, Tartrates, Physical sciences, Combination drugs, Barrier contraception, Lactic acid/citric acid/potassium bitartrate, Spermicide, Vagina, Bitartrate, Acids in wine, Lactic

SAN DIEGO, July 28, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter endedJune 30, 2021on Wednesday, August 11, 2021 at 4:30 p.m.

Key Points: 
  • SAN DIEGO, July 28, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter endedJune 30, 2021on Wednesday, August 11, 2021 at 4:30 p.m.
  • The webcast (live and archived) and related slide presentation can be accessed through https://evofem.investorroom.com/2021Q2Results or directly at https://edge.media-server.com/mmc/p/h6zpy9h5 .
  • Atelephone replay will be available for 24 hours after the call at(855) 859-2056 (U.S.) or(404) 537-3406 (International), conference ID 9190716.
  • The Company launched its first FDA-approved commercial product, Phexxi (lactic acid, citric acid and potassium bitartrate), inthe United StatesinSeptember 2020.

Evofem Biosciences to Present at Jefferies Virtual Healthcare Conference 2021

Retrieved on: 
Tuesday, June 1, 2021
Infectious causes of cancer, Chlamydiae, Sexually transmitted diseases and infections, Medical specialties, Pathogenic bacteria, Bacteria, Clinical medicine, Mycoplasma, Lactic acid/citric acid/potassium bitartrate, Sexually transmitted infection, Bitartrate, Chlamydia

Evofem Biosciences, Inc., (NASDAQ:EVFM) is developing and commercializing innovativeproducts to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs).

Key Points: 
  • Evofem Biosciences, Inc., (NASDAQ:EVFM) is developing and commercializing innovativeproducts to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs).
  • The Company launched its first FDA-approved commercial product, Phexxi (lactic acid, citric acid and potassium bitartrate), inthe United StatesinSeptember 2020.
  • The Company is evaluating lead product candidate EVO100 for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, 'EVOGUARD .'
  • Phexxiis a registered trademark of Evofem Biosciences, Inc.

Evofem Biosciences Wins Business Intelligence Group's BIG Innovation Award 2021

Retrieved on: 
Tuesday, January 12, 2021
Chemical compounds, Chemistry, Chemical substances, Barrier contraception, Lactic acid/citric acid/potassium bitartrate, Spermicide, Vagina, Food acidity regulators, Acids in wine, Bitartrate, Citric acid, Lactic

SAN DIEGO, Jan. 12, 2021 /PRNewswire/ --Evofem Biosciences, Inc., (NASDAQ: EVFM) has been named a winner of Business Intelligence Group's 2021 BIG Innovation Award sfor outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi (lactic acid, citric acid and potassium bitartrate) .

Key Points: 
  • SAN DIEGO, Jan. 12, 2021 /PRNewswire/ --Evofem Biosciences, Inc., (NASDAQ: EVFM) has been named a winner of Business Intelligence Group's 2021 BIG Innovation Award sfor outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi (lactic acid, citric acid and potassium bitartrate) .
  • We know firsthand about the serious responsibility and impact of family planning," said Saundra Pelletier, Chief Executive Officer, Evofem Biosciences.
  • The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world.
  • Unlike other industry award programs, these programs are judged by business executives having experience and knowledge.

Evofem Biosciences Announces Presentations on Phexxi and EVO100 at Key Medical Society Meetings

Retrieved on: 
Wednesday, October 7, 2020
Human reproduction, Chemical substances, Chemical compounds, Barrier contraception, Lactic acid/citric acid/potassium bitartrate, Vagina, Bitartrate, Citric acid, Acids in wine, Spermicide

Subjects were randomized to receive either EVO100 vaginal gel or placebo vaginal gel.

Key Points: 
  • Subjects were randomized to receive either EVO100 vaginal gel or placebo vaginal gel.
  • The primary and secondary endpoints of the study were the reduction in the incidence of urogenitalChlamydia trachomatisandNeisseria gonorrhea, respectively.
  • WHAT ARE THE POSSIBLE SIDE EFFECTS OF PHEXXI (lactic acid, citric acid, and potassium bitartrate) vaginal gel 1.8%, 1%, 0.4%?
  • Evofem does not undertake any duty to update any forward-looking statement except as required by law.

Evofem Biosciences Announces U.S. Commercial Launch of Phexxi™ (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal, On-Demand Prescription Contraceptive Vaginal Gel

Retrieved on: 
Tuesday, September 8, 2020
Chemical substances, Chemistry, Chemical compounds, Barrier contraception, Lactic acid/citric acid/potassium bitartrate, Food acidity regulators, Acids in wine, Bitartrate, Citric acid, Potassium bitartrate, Vagina, Lactic

Evofem is also launching the Phexxi Concierge Experience, a comprehensive woman-centric telemedicine support system to help ensure Phexxi is accessible to all women who need it.

Key Points: 
  • Evofem is also launching the Phexxi Concierge Experience, a comprehensive woman-centric telemedicine support system to help ensure Phexxi is accessible to all women who need it.
  • Phexxi is a prescription vaginal gel used to prevent pregnancy in females who choose to use an on-demand method of birth control.
  • Avoid Phexxi if you or your sexual partner is allergic to lactic acid, citric acid, potassium bitartrate, or any of the ingredients in Phexxi.
  • The Company's first commercial product, Phexxi (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved inthe United Statesfor the prevention of pregnancy.

Horizon Therapeutics plc Announces Availability of PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets in the United States

Retrieved on: 
Monday, April 27, 2020
FDA, Health, Family, Consumer, Pharmaceutical, Research, Parenting, Infectious diseases, Children, General Health, Other Consumer, Science, Seniors, Clinical trials, Amines, Cysteamine, Thiols, Cystinosis, Transmission Control Protocol, Bitartrate, Health, Chemistry, Medicine, Nephropathic Cystinosis, PROCYSBI, Horizon

In the United States, PROCYSBI is now available in two forms: tear-open packets and capsules.

Key Points: 
  • In the United States, PROCYSBI is now available in two forms: tear-open packets and capsules.
  • Additionally, the ability to access PROCYSBI granules in tear-open packets may help reduce the burden families living with cystinosis often face with managing multiple medications every day.
  • The coating of PROCYSBI granules in tear-open packets and inside the capsules is designed to break down in low acid environments.
  • This press release contains forward-looking statements, including statements regarding the potential benefits of availability of PROCYSBI (cysteamine bitartrate) delayed-release oral granules in packets.

2020 Analysis on the Hydrocodone Bitartrate Industry - Trends & Developments, Major Players, Patents and More

Retrieved on: 
Thursday, March 26, 2020
Morphinans, Euphoriants, RTT, Psychoactive drugs, Bitartrate, Hydrocodone

DUBLIN, March 26, 2020 /PRNewswire/ -- The "Hydrocodone Bitartrate (CAS 143-71-5) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 26, 2020 /PRNewswire/ -- The "Hydrocodone Bitartrate (CAS 143-71-5) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Hydrocodone bitartrate.
  • The Hydrocodone bitartrate global market report key points:
    The first chapter introduces the product (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The fifth chapter deals with Hydrocodone Bitartrate market trends and forecast, distinguish Hydrocodone Bitartrate manufacturers and suppliers.

Hydrocodone Bitartrate (CAS 143-71-5) Markets, 2020: Trends & Developments, Major Players, Patents, and More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 25, 2020
Chemicals, Plastics, Manufacturing, Morphinans, Euphoriants, RTT, Psychoactive drugs, Bitartrate, Hydrocodone

The "Hydrocodone Bitartrate (CAS 143-71-5) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hydrocodone Bitartrate (CAS 143-71-5) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Hydrocodone bitartrate.
  • The Hydrocodone bitartrate global market report key points:
    The first chapter introduces the product (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The fifth chapter deals with Hydrocodone Bitartrate market trends and forecast, distinguish Hydrocodone Bitartrate manufacturers and suppliers.

Patented Medicine Prices Review Board issues a Notice of Hearing for allegations of excessive pricing of Procysbi

Retrieved on: 
Wednesday, January 16, 2019
Chemistry, Orphan drugs, Health, Patented Medicine Prices Review Board, Medication, Bitartrate, Cysteamine, United States antitrust law

OTTAWA, Jan. 16, 2019 /CNW/ - The Patented Medicine Prices Review Board will hold a public hearing in the matter of the price of the patented medicine cysteamine bitartrate, sold under the trade name Procysbi by the patentee Horizon Therapeutics Canada.

Key Points: 
  • OTTAWA, Jan. 16, 2019 /CNW/ - The Patented Medicine Prices Review Board will hold a public hearing in the matter of the price of the patented medicine cysteamine bitartrate, sold under the trade name Procysbi by the patentee Horizon Therapeutics Canada.
  • For further information on the application process, please contact:
    The Patented Medicine Prices Review Board is an independent quasi-judicial body that protects the interests of Canadian consumers by ensuring the prices of patented medicines sold in Canada are not excessive.
  • Board Staff review the prices that patentees charge for each individual patented drug product sold in Canadian markets on an ongoing basis.
  • If the Board finds, as the result of a public hearing, that the price of a patented drug is excessive, the Board may issue a remedial order to the patentee.